Company / Cash & Equivalents
Neogen Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$129.0M
FY2025
5-year range
$44.5M / $170.6M
FY2021-FY2025
Trend
-24.4%
vs FY2024
Sector context
#104 of 152
Health Care
What the data says
At $129M, Neogen's cash & equivalents ranks #104 of 152 in the Health Care sector. Cash & Equivalents has fluctuated over the past 10 years, ranging from $42M in FY2019 to $171M in FY2024.
Based on SEC 10-K filings.
$129M in FY2025 with a 5-year CAGR of +14.3%.
Declined from $163M to $129M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +42.6%
- 5-Year CAGR
- +14.3%
- 10-Year CAGR
- -
Sector benchmark
#104 of 152 in Health CareTop 68% of 152This company $129.0M Sector average $1.2B
▼
-89.0% below sector average
Key checks
Key Insights
- 5-year CAGR of +14.3%, indicating consistent growth.
- In FY2025, cash & equivalents decreased 24.4% year-over-year.
- Ranks #104 out of 152 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score 0.59 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $129.0M | -24.4% |
| FY2024 | $170.6M | +4.5% |
| FY2023 | $163.2M | +267.1% |
| FY2022 | $44.5M | -41.2% |
| FY2021 | $75.6M | +14.1% |
| FY2020 | $66.3M | +59.0% |
| FY2019 | $41.7M | -49.8% |
| FY2018 | $83.1M | +7.1% |
| FY2017 | $77.6M | +40.4% |
| FY2016 | $55.3M | -16.4% |
As of FY2025 · SEC 10-K · Updated Mar 28, 2026